Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for AZD-6244 (compound)
Most Correlated Studies
- Uveal melanoma cell lines reponses to selumetinib treatment
- Oncogenic NRAS signaling in melanoma allograft tumors
- Colorectal cancer cells treated with tankyrases and MEK inhibitors
- Lungs of mice with TGF-alpha induced fibrosis, treated with MAPK (ARRY) and PI3K (PX-886) inhibitors
- Lung cancer HCC827 EGFR-mutant cells following treatment with targeted therapies
Most Relevant Literature
- Induction of COX-2 by feline calicivirus via activation of the MEK1-ERK1/2 pathway, and attenuation …
- The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calr…
- Novel LC-MS/MS method for the determination of selumetinib (AZD6244) in whole blood collected with v…
- The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
- Delineation of prototypical degradation mechanism, characterization of unknown degradation impuritie…
Most Relevant Clinical Trials
- Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
- Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
- Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
- Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With …
- Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodg…
